Posts by: Vijaya Iyer

News

The Pulmonary Fibrosis Foundations (PFF)’ Patient Registry is providing valuable data to support pulmonary fibrosis research, as evidenced by multiple presentations at the 2019 American Thoracic Society (ATS) conference, held ... Read more

May 29, 2019June 18, 2019

First Patient Dosed in Phase 2b Study Testing Inhaled RVT-1601 for IPF Cough

News

The first patient was dosed in a Phase 2b clinical trial investigating the safety and effectiveness of Respivant Biosciences’ inhalation therapy candidate RVT-1601 for idiopathic pulmonary fibrosis patients with persistent cough. ... Read more

May 14, 2019May 14, 2019

Exhaled Nitric Oxide a Potential Biomarker for IPF Severity and Progression, Study Suggests

News

High levels of nitric oxide in the lungs of people with idiopathic pulmonary fibrosis (IPF) are associated with faster disease progression and worse survival, researchers in Italy report. The ... Read more

March 1, 2019March 1, 2019

Feldman Family Foundation to Host Poker Night to Support PF Research, Awareness

News

The Feldman Family Foundation is hosting a pulmonary fibrosis fund-raising event — its 6th Annual Texas Hold ‘Em Tournament and Casino Night — on Saturday (March 2), at the Chevy Chase ... Read more

February 27, 2019February 27, 2019

Proton Radiation Therapy Improves Survival in Lung Cancer Patients with IPF, Study Finds

News

Lung cancer patients with underlying idiopathic pulmonary fibrosis (IPF) treated with proton radiation therapy live longer than those treated with X-ray irradiation, a study shows. Additionally, fewer occurrences of treatment-related lung ... Read more

January 21, 2019January 24, 2019

Experimental IPF Therapy BBT-877 Gets FDA’s Orphan Drug Status

News

Bridge Biotherapeutics’ investigational therapy candidate BBT-877 for idiopathic pulmonary fibrosis (IPF) has been awarded orphan drug designation by the U.S. Food and Drug Administration (FDA). According to the company, BBT-877 ... Read more

January 8, 2019January 14, 2019

Promedior’s Experimental IPF Therapy PRM-151 to Enter Phase 3 Stage

News

Promedior plans to begin Phase 3 testing of its investigational therapy PRM-151 for the treatment of idiopathic pulmonary fibrosis (IPF), now that the U.S. Food and Drug Administration has ... Read more

November 5, 2018November 8, 2018

Phase 2 Trial Now Underway to Test Galapagos’ GLPG1205 in IPF Patients

News

Galapagos has launched a Phase 2 trial testing the safety and effectiveness of their investigational new therapy called GLPG1205 in patients with idiopathic pulmonary fibrosis (IPF), reporting that the first ... Read more

October 26, 2018November 2, 2018

IPF and Interstitial Lung Disease in Rheumatoid Arthritis Share Genetic Risk Factor

News

A mutation associated with the mucous-producing gene MUC5B, a known genetic risk factor for idiopathic pulmonary fibrosis (IPF), also is prevalent in rheumatoid arthritis patients with interstitial lung disease (ILD), ... Read more

October 8, 2018October 11, 2018

X-Rx Completes Early Studies on X-165 for Potential IPF Treatment, Supporting IND Application

News

Studies supporting an investigational new drug (IND) application for X-165, a potential candidate for the treatment of idiopathic pulmonary fibrosis (IPF) and other fibrotic disorders, have been completed, X-Rx ... Read more

Posts by: Vijaya Iyer

Vijaya Iyer

Several PFF Registry-based Studies Presented at American Thoracic Society Conference

First Patient Dosed in Phase 2b Study Testing Inhaled RVT-1601 for IPF Cough

Exhaled Nitric Oxide a Potential Biomarker for IPF Severity and Progression, Study Suggests

Feldman Family Foundation to Host Poker Night to Support PF Research, Awareness

Proton Radiation Therapy Improves Survival in Lung Cancer Patients with IPF, Study Finds

Experimental IPF Therapy BBT-877 Gets FDA’s Orphan Drug Status

Promedior’s Experimental IPF Therapy PRM-151 to Enter Phase 3 Stage

Phase 2 Trial Now Underway to Test Galapagos’ GLPG1205 in IPF Patients

IPF and Interstitial Lung Disease in Rheumatoid Arthritis Share Genetic Risk Factor

X-Rx Completes Early Studies on X-165 for Potential IPF Treatment, Supporting IND Application

Pin It on Pinterest